3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
23
Waldenstrom Macroglobulinemia
1
Recurrence
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Leukemia, Plasma Cell
1
Interventions
venetoclax
6
ibrutinib
4
pirtobrutinib
2
Sirolimus
2
Rituximab
2
Mycophenolic Acid
2
Cyclosporine
2
Cyclophosphamide
2
zanubrutinib
1
pembrolizumab
1
loncastuximab tesirine
1
fludarabine phosphate
1
carfilzomib
1
acalabrutinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Specimen Handling
1
Rifaximin
1
Peripheral Blood Stem Cell Transplantation
1
Methotrexate
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Etoposide
1
Dexamethasone
1
Cyclosporins
1
Calcium Dobesilate
1
CT-P10
1
Busulfan
1
Biopsy
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
carfilzomib
×
30 days
×
Clear all
NCT04263480
2026-05-12
CZAR-1
University of Ulm
Phase 2
Active not recruiting
99 enrolled